55 filings
8-K
INBX
Inhibrx Inc
30 May 24
Termination of a Material Definitive Agreement
4:13pm
8-K
INBX
Inhibrx Inc
24 May 24
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
4:08pm
8-K
INBX
Inhibrx Inc
17 May 24
Other Events
5:29pm
8-K
INBX
Inhibrx Inc
9 May 24
Inhibrx Reports First Quarter 2024 Financial Results
4:08pm
8-K
INBX
Inhibrx Inc
8 May 24
Other Events
4:42pm
8-K
cv48va
12 Mar 24
Other Events
4:02pm
8-K
8vjx5
28 Feb 24
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9:12am
8-K
k7ms3gsfdaxefw4b2rgy
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
ymut8fbv54a41zsjh
9 Nov 23
Inhibrx Reports Third Quarter 2023 Financial Results
4:03pm
8-K
y7iamnod4m
2 Nov 23
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
9:16am
8-K
eq92bhvdst4fwmjbb
19 Sep 23
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
4:03pm
8-K
dose1 hed9
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
8-K
dzpkxgsl
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
0t9r o0g3pf70ggdgj
30 May 23
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:03am
8-K
r9x qilcbr00vrrhelx
25 May 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
9dumkkc1
8 May 23
Inhibrx Reports First Quarter 2023 Financial Results
4:05pm
8-K
e990wxraygec4
26 Apr 23
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
9:01am
8-K
u8pxh0a19
10 Mar 23
Regulation FD Disclosure
7:02pm
8-K
xutgn67
6 Mar 23
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
4:04pm
8-K
c7m8u3nfy74
16 Nov 22
Regulation FD Disclosure
9:01am